NEW YORK and JERUSALEM, Dec. 6,
2021 /PRNewswire/ -- Dr. Morris C.
Laster ("Dr. Laster"), who, together with the other proxy
participants, beneficially owns 6,006,000 shares of common stock,
par value $0.001 in Scopus BioPharma
Inc. (Nasdaq: SCPS) ("Scopus" or the "Company"), issued an open
letter to Scopus stockholders today in connection with the
Company's upcoming Annual Meeting. The open
letter highlights the following key points and encourages
stockholders to vote for Dr. Laster's director nominees:
- The Company's continuing financial underperformance and
plummeting stock price demonstrate the ineffectiveness of
management and the current Board of Directors.
- The Company continues to engage in dilutive equity issuances,
self-dealing, and related party transactions with HCFP/Capital
Partners and its affiliates, to the detriment of Scopus
stockholders.
- The Company continues to misrepresent key facts regarding the
ongoing litigation with Dr. Laster in the Delaware Court of Chancery.
- The Stockholder Group calls on the Company to completely
resolve the litigation.
- The current Board has failed – do the right thing and vote them
out!
Dr. Laster urges ALL Scopus stockholders to vote on the
BLUE proxy card "FOR" the election of Dr. Laster's
highly qualified director nominees, Mordechai Saar Hacham and Joshua Levine. Doing so will send a strong
message to Scopus's management and Board that stockholders want new
directors who will act as responsible, independent stewards of this
public company.
Stockholders of record as of August 16,
2021 are entitled to vote at the Annual Meeting on
December 20 and may obtain a copy of
Dr. Laster's proxy materials and the BLUE proxy card by
contacting Dr. Laster's proxy solicitation agent, Georgeson LLC,
toll-free at (866) 695-6078.
Dr. Laster's letter to Scopus stockholders can be found at:
https://www.sec.gov/Archives/edgar/data/0001772028/000110465921145931/tm2133704d1_dfan14a.htm
Certain Information Concerning the Participants
Dr. Laster, together with the other proxy participants, has
filed a proxy statement and accompanying BLUE proxy card with the
SEC to be used to solicit votes for the election of his slate of
highly-qualified director nominees at the Company's 2021 Annual
Stockholder Meeting.
The participants in the proxy solicitation are Dr. Morris C. Laster, Chen
Laster, Gabriella Laster,
Sara Laster, Mordechai Saar Hacham and Joshua Levine.
As of the date hereof, Dr. Laster beneficially owns 6,006,000
shares of shares of common stock, par value $0.001 per share of the Company ("Common Stock"),
comprised of (i) 4,926,000 shares of Common Stock over which Dr.
Laster claims sole beneficial ownership and (ii) 360,000 shares of
Common Stock held by each of his daughters, Chen Laster, Gabriella
Laster and Sara Laster, or
1,080,000 shares of Common Stock in the aggregate, over which Dr.
Laster claims shared beneficial ownership on account of Dr. Laster,
Chen Laster, Gabriella Laster and Sara Laster constituting a group. As of the date
hereof, none of Messrs. Hacham or Levine beneficially own any
shares of Common Stock.
View original
content:https://www.prnewswire.com/news-releases/dr-morris-c-laster-issues-an-open-letter-to-scopus-biopharma-inc-stockholders-in-connection-with-upcoming-annual-meeting-301437169.html
SOURCE Dr. Morris C. Laster